A First In-Human Study of Novel PI3K Inhibitor IPI-549 in Patients With Advanced Solid Tumors

In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer.

In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.

Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple myeloma.

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung cancer with MET exon 14 skipping alterations eligible for tepotinib.

During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in patients with squamous non–small cell lung cancer.